Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 01/07/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 2087 publications

Head and neck atopic Dermatitis: are janus kinase inhibitors a game changer?

Head and neck atopic Dermatitis: are janus kinase inhibitors a game changer?

Journal: Expert opinion on pharmacotherapy
Published: December 14, 2025

An oral lichen planus-like mouse model driven by IFN-γ signaling and cytotoxic CD8+ T cells.

An oral lichen planus-like mouse model driven by IFN-γ signaling and cytotoxic CD8+ T cells.

Journal: JCI insight
Published: December 11, 2025

Immune control of functional memory CD8 T cells in normal-appearing vitiligo skin.

Immune control of functional memory CD8 T cells in normal-appearing vitiligo skin.

Journal: Science advances
Published: December 10, 2025

Preventive Effectiveness of Recombinant Zoster Vaccine in Rheumatoid Arthritis Patients Treated with Janus Kinase Inhibitors.

Preventive Effectiveness of Recombinant Zoster Vaccine in Rheumatoid Arthritis Patients Treated with Janus Kinase Inhibitors.

Journal: Internal medicine (Tokyo, Japan)
Published: December 10, 2025

Correction to: Bone Mineral Density During Treatment with The Janus Kinase Inhibitor Baricitinib in Patients with Rheumatoid Arthritis: A Monocentric Observational Study.

Correction to: Bone Mineral Density During Treatment with The Janus Kinase Inhibitor Baricitinib in Patients with Rheumatoid Arthritis: A Monocentric Observational Study.

Journal: Calcified tissue international
Published: December 08, 2025

Targeting the JAK/STAT pathway in palmoplantar pustulosis: a review.

Targeting the JAK/STAT pathway in palmoplantar pustulosis: a review.

Journal: Annals of medicine
Published: December 02, 2025

Maintained improvement of outcomes related to skin clearance, itch, sleep and quality of life with baricitinib in adults with moderate-to-severe Atopic Dermatitis who were treated for up to 200 weeks in a randomized trial.

Maintained improvement of outcomes related to skin clearance, itch, sleep and quality of life with baricitinib in adults with moderate-to-severe Atopic Dermatitis who were treated for up to 200 weeks in a randomized trial.

Journal: The Journal of dermatological treatment
Published: November 27, 2025

Disruption of metabolic licensing by JAK inhibitors constrains CD8 T cell activation and effector function.

Disruption of metabolic licensing by JAK inhibitors constrains CD8 T cell activation and effector function.

Journal: Research square
Published: November 24, 2025

SAMHD1 promotes SARS-CoV-2 infection by enhancing HNF1-dependent ACE2 expression in lung epithelial cells.

SAMHD1 promotes SARS-CoV-2 infection by enhancing HNF1-dependent ACE2 expression in lung epithelial cells.

Journal: bioRxiv : the preprint server for biology
Published: November 24, 2025

Disruption of metabolic licensing by JAK inhibitors constrains CD8 T cell activation and effector function.

Disruption of metabolic licensing by JAK inhibitors constrains CD8 T cell activation and effector function.

Journal: Research square
Published: November 24, 2025

Effectiveness and safety of Baricitinib in alopecia areata: a prospective cohort study.

Effectiveness and safety of Baricitinib in alopecia areata: a prospective cohort study.

Journal: The Journal of dermatological treatment
Published: November 24, 2025

Drug retention rate of Janus kinase inhibitors in patients with rheumatoid arthritis: the KEIO-RA cohort study.

Drug retention rate of Janus kinase inhibitors in patients with rheumatoid arthritis: the KEIO-RA cohort study.

Journal: Immunological medicine
Published: November 24, 2025
Showing 1-12 of 2,087

Last Updated: 01/07/2026